http://www.fpnotebook.com/
CalcipotrieneAka: Donovex
- Indication
- Dosing
- Ointment applied qd-bid
- Efficacy
- Begin to see benefit in 2 weeks
- Maximum benefit in 6-8 weeks
- Resolution in 10% of patients
- Moderate Improvement in 70% of patients
- No Improvement in 20% of patients
- Useful adjunct to PUVA
- Adverse effects
- May be irritating, more so in fold areas
- Do not use on face
- Vitamin D analog - risk of Hypercalcemia
- Limit to 100 grams per week
- Disadvantages
- Expensive ($100 for 2 ounces)
calcipotriene (C0065767) | |
|---|---|
| Definition (NCI) | A synthetic vitamin D derivative usually formulated for topical dermatological use, antipsoriatic Calcipotriene (calcipotriol) competes equally with active 1,25-hydroxy-2D3 (the natural form of vitamin D) for 1,25-hydroxy-2D3 receptors in regulating cell proliferation and differentiation. It induces differentiation and suppresses proliferation of keratinocytes, reversing abnormal keratinocyte changes in psoriasis, and leads to normalization of epidermal growth. (NCI04) |
| Concepts | Organic Chemical (T109) , Pharmacologic Substance (T121) |
| MSH | C055085 |
| English | calcipotriene, Calcipotriene preparation, Calcipotriol |
| Spanish | calcipotrieno, calcipotriol, preparado con calcipotrieno, preparado de calcipotrieno |
| Parent Concepts | Anti-psoriatic Agent (C1516001), Calcitriol (C0006674), [DE802] ANTIPSORIATICS, TOPICAL (C0991606), Antimitotic Agents (C0003379), Vitamin D (C0042866), Duplicate concept (C1274013), Topical skin agent (C1629038), Dermatological Vitamin D Analogs (C1579284) |
| Sources | MSH, MTHSPL, NCI, NDFRT, RXNORM, SCTSPA, SNOMEDCT, USPMG, VANDF Derived from the NIH UMLS (Unified Medical Language System) |
